TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04974892

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Blood tests will be taken at 12, 20, 28 and 36 weeks gestation to assess the immune profile and omic profile.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Blood tests will be taken at 12, 20, 28 and 36 weeks gestation to assess the immune profile and omic profile.
Study: NCT06084702

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehydration with plain water
Description: Plain water without calories, sweetener, or electolytes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehydration Drink
Description: Roaring Water. An electrolyte drink with low Carbohydrate content
Study: NCT04984122

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LEEP
Description: According to the size of the cervix, a loop electrode size was selected. The electrical power for the loop electrode was set to 50 W cut and 45 W coagulation in blended mode. LEEP was performed by carefully passing the loop around the transformation zone from 12 o'clock to 6 o'clock. An additional top-hat excision was performed in patients with a lesion deep in the cervical canal. After completion of the excision, hemostasis was exclusively obtained using the ball electrode in spray coagulation mode. No suturing or other methods were used for hemostasis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LEEP
Description: According to the size of the cervix, a loop electrode size was selected. The electrical power for the loop electrode was set to 50 W cut and 45 W coagulation in blended mode. LEEP was performed by carefully passing the loop around the transformation zone from 12 o'clock to 6 o'clock. An additional top-hat excision was performed in patients with a lesion deep in the cervical canal. After completion of the excision, hemostasis was exclusively obtained using the ball electrode in spray coagulation mode. No suturing or other methods were used for hemostasis.
Study: NCT05822193

Intervention type: OTHER
Intervention: Multiple exposures
Description: Exposures variables (observational study): age, gender, education, comorbidities, vaccination status, severity of the acute episode of COVID-19, treatments used for acute COVID-19.
Study: NCT05276206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID , NALUFIN , local anesthetic andTAP Block
Description: The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID , NALUFIN , local anesthetic andTAP Block
Description: The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID , NALUFIN , local anesthetic andTAP Block
Description: The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID , NALUFIN , local anesthetic andTAP Block
Description: The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared
Study: NCT04626258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazol once a month 150 mg capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-Mesitran
Description: The first month apply every day one sachet, the next five months apply every week one sachet.
Study: NCT05498597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-151
Description: Administered intravenously
Study: NCT06462898

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fortified Protein Smoothie
Description: Omega-3 powder and protein supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-Fortified Protein Smoothie
Description: Protein without omega-3 powder supplementation.
Study: NCT05693753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of XCM for the treatment of MAGRs with mCAF technique
Description: After local anaesthesia, mCAF technique will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of MAGRs with CTG
Description: After local anaesthesia, mCAF technique will be performed. CTG will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
Study: NCT04421352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned.
Study: NCT05038683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holbæk Obesity Treatment
Description: Obesity is a chronic, progressive, severe, recidivistic, and complex disease, which mandates that children and adolescents with overweight or obesity have access to a professional medical healthcare service as other pediatric chronic diseases, implying a lifelong course of treatment. The HOT method is further based on the physiological insight into the endocrine regulation of fat mass; especially on how the body adapts when it is challenged by weight loss. These insights include an understanding where the body shifts into an energy-preserving mode when the individual is initiating weight-reducing actions, such as a reduced caloric intake or an increased level of physical activity, which has numerous impacts on communication and pedagogy.~HOT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Obesity Treatment
Description: Obesity is viewed as a chronic disease that is ultimately thought to result from an imbalance between energy intake and energy expenditure. However, multiple factors, both environmental and genetic, are thought to influence the disease as well. As obesity reflects energy imbalances, the treatment plan should be designed to induce a slightly negative energy balance by focusing on diet, physical activity, and inactivity through behavior change. Taking one step at a time, will in the end lead to the same energy balance result (i.e. weight loss) and will be more sustainable for the participant whose motivation is absolutely pivotal in this process.~COT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months.
Study: NCT05618288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile Health Breastfeeding Counseling
Description: a phone-based breastfeeding counseling intervention, delivered by labor and delivery nurses, nutritionists, and maternal and child health nurses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care breastfeeding counseling
Description: The ongoing antenatal, delivery and postnatal breastfeeding and lactation counseling that is provided by the Naivasha sub-County Referral Hospital.
Study: NCT02953496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonapanitase
Description: Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
Study: NCT06344559

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The study intervention involves modulation of cortical excitation to inhibition (E/I) balance in the right frontal eye field (FEF) by means of 2 trains of spaced continuous or intermittent theta burst stimulation (cTBS, iTBS, respectively) using a transcranial magnetic stimulation device. The endpoint of this stimulation will be a decrease (cTBS) or increase (iTBS) in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2016).~In separate sessions, all participants will receive either active or stimulation to the FEF. The Investigators will contrast the effects of both iTBS and cTBS to sham stimulation and to each other.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The study intervention involves modulation of cortical excitation to inhibition (E/I) balance in the right frontal eye field (FEF) by means of 2 trains of spaced continuous or intermittent theta burst stimulation (cTBS, iTBS, respectively) using a transcranial magnetic stimulation device. The endpoint of this stimulation will be a decrease (cTBS) or increase (iTBS) in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2016).~In separate sessions, all participants will receive either active or stimulation to the FEF. The Investigators will contrast the effects of both iTBS and cTBS to sham stimulation and to each other.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The study intervention involves modulation of cortical excitation to inhibition (E/I) balance in the right frontal eye field (FEF) by means of 2 trains of spaced continuous or intermittent theta burst stimulation (cTBS, iTBS, respectively) using a transcranial magnetic stimulation device. The endpoint of this stimulation will be a decrease (cTBS) or increase (iTBS) in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2016).~In separate sessions, all participants will receive either active or stimulation to the FEF. The Investigators will contrast the effects of both iTBS and cTBS to sham stimulation and to each other.
Study: NCT06039072

Intervention type: DRUG
Intervention: Patients with cardiac function recovered for more than one year and discontinued were in the discontinuation group.
Description: Among the patients with perinatal cardiomyopathy who were included in the study, their heart function returned to normal in 1 year after receiving standardized treatment, and then after another 1 year of standardized treatment to respect the patients' individual wishes, fully inform the patients of the relevant information and potential risks, including the possibility of deterioration of heart function after discontinuation of the medication, and only after obtaining the patients' informed consent and signing the informed consent form could they be included in the discontinuation group, and the rest were in the non-discontinuation group.
Study: NCT04694976

Intervention type: BIOLOGICAL
Intervention: 25-OH Vitamin D measure
Description: As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.
Study: NCT05139420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phentermine-topiramate combined with lifestyle intervention
Description: participants will be enrolled in a medical weight loss program and will be offered a 6 month prescription for phentermine-topiramate (note: The goal of the study is NOT to assess efficacy or safety of this drug) in addition to lifestyle advice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle intervention with meal replacement program
Description: participants will be enrolled in a medical weight loss program and will be given a 6 month subscription to a calorie-reduced meal replacement program, in addition to lifestyle advice.
Study: NCT05115110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7204239
Description: RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered Q4W by SC injection into the abdomen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risdiplam
Description: Risdiplam will be administered orally once daily (QD) for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally once daily (QD) for the duration of the study.
Study: NCT06449222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 1 (DL1)
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 1 (DL2)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-placlitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-placlitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Optimized Dose
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Equivalent Q3W Dose
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Equivalent Q3W Dose
Description: IV infusion
Study: NCT05463731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug (IV)
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug (IV)
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug (SC)
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug (SC)
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV or SC
Study: NCT06470763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV600
Description: ANV600 administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV600 + pembrolizumab (KEYTRUDA®)
Description: ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion
Study: NCT06541548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal.
Study: NCT05849363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression
Description: Posterior fossa decompression：Posterior arch of atlas removal, decompression of cerebellum, detection of foramen magnum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Compression-Distraction-Reduction-Fixation
Description: Posterior Compression-Distraction-Reduction-Fixation：After subperiosteal dissection, the facet joint was exposed. A 2-mm joint scraper with sharp edge was inserted into the joint capsule and rotated to remove the articular cartilage. A blunt-edged rotating distractor was then inserted into the joint space, and the facet was sequentially opened with larger and larger blunt rotating distractors. After distraction on one side, an appropriate-sized trial was placed into the contralateral facet, holding the distraction open. This was repeated back and forth with larger trials. These steps were repeated, and the facet joints were distracted up to the pre-planned distance of the odontoid tip above Chamberlain's line.
Study: NCT06541548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pQCT
Description: Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pQCT
Description: Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXA
Description: The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXA
Description: The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck.
Study: NCT06029010

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Follow clinical administration.

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Follow clinical administration.
Study: NCT05417867

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of stool and blood samples

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT04539366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-CAR-expressing Autologous T-lymphocytes
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Procedure
Description: Undergo standard imaging scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging of the Heart
Description: Undergo cardiac MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05803811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Colon delivered vitamin B2 (Riboflavin) for 12 weeks
Study: NCT01499693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Pantoprazole 20 mg
Description: oral dose, twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Pantoprazole 40 mg
Description: oral dose, once a day (morning)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral dose, once a day (night)~Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group).
Study: NCT06431984

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: prick test
Description: self-sampling of capillary blood using the finger prick test method
Study: NCT05803811

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Riboflavin
Description: Colon delivered vitamin B2 (Riboflavin) for 12 weeks
Study: NCT05543928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101
Description: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05803811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Colon delivered vitamin B2 (Riboflavin) for 12 weeks
Study: NCT06555744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW191
Description: Administered intravenously
Study: NCT05144633

Intervention type: DEVICE
Intervention: Auscultation
Description: This study will be to determine if the addition of Eko AI-assisted lung auscultation examination to a standard of care Pulmonary POCUS + assists with acute respiratory failure diagnosis.